Internal Medicine, Critical Care Medicine · Burleson, TX
NPI
1154371078
Since 2006
Specialty
Internal Medicine, Critical Care Medicine
Code 207RC0200X
Group practices
0
Medicare group memberships
Hospitals
2
Hospital affiliations
11807 South Fwy Ste 362
Burleson, TX, 76028
Phone (817) 568-0004
Medicare paid, 2024
$231K
2,761 services
Medicare patients, 2024
624
Average age 73
Drug cost, 2024
$2.3M
4,422 prescriptions
Company payments, 2025
$614
From 8 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Hisham Bismar was code 99232 (hospital e&m - subsequent), 926 times for 172 patients. In total Hisham Bismar billed 2,761 services in 20 codes, and Medicare paid $231K.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2026-07-20.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| 99232 Hospital E&M - Subsequent | Facility | 926 | 172 | $59.85 | $55K |
| 99214 Office E&M - Established | Office | 806 | 401 | $92.38 | $74K |
| 99223 Hospital E&M - Initial | Facility | 165 | 144 | $126.30 | $21K |
| 94060 Pulmonary Function Testing | Office | 162 | 158 | $29.58 | $4,791 |
| 99215 Office E&M - Established | Office | 153 | 110 | $141.29 | $22K |
| 99233 Hospital E&M - Subsequent | Facility | 150 | 45 | $90.87 | $14K |
| 94618 Pulmonary Function Testing | Office | 114 | 106 | $26.11 | $2,977 |
| 99205 Office E&M - New | Office | 96 | 96 | $160.48 | $15K |
| 99291 Critical Care E&M | Facility | 85 | 30 | $157.55 | $13K |
| 95811 Sleep Study | Facility | 28 | 25 | $94.43 | $2,644 |
| 95810 Sleep Study | Facility | 24 | 22 | $87.15 | $2,092 |
By year: 2022 $342K for 3,645 services; 2023 $252K for 2,692 services; 2024 $231K for 2,761 services.
Medicare prescription drug claims, 2024
In 2024, the drug Hisham Bismar prescribed most often to Medicare patients was Trelegy Ellipta (Fluticasone/Umeclidin/Vilanter), with 723 prescriptions and refills. In total Hisham Bismar wrote 4,422 Medicare prescriptions that cost $2.3M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Trelegy Ellipta Fluticasone/Umeclidin/Vilanter | 723 | 1,329 | 241 | $840K |
| Albuterol Sulfate Hfa Albuterol Sulfate | 660 | 1,157 | 326 | $24K |
| Montelukast Sodium Generic | 562 | 1,541 | 206 | $5,357 |
| Prednisone Generic | 488 | 577 | 325 | $2,112 |
| Breztri Aerosphere Budesonide/Glycopyr/Formoterol | 383 | 704 | 149 | $444K |
| Doxycycline Hyclate Generic | 304 | 304 | 235 | $2,367 |
| Fluticasone-Salmeterol Fluticasone Propion/Salmeterol | 109 | 220 | 45 | $18K |
| Symbicort Budesonide/Formoterol Fumarate | 106 | 171 | 42 | $40K |
| Breo Ellipta Fluticasone/Vilanterol | 99 | 180 | 36 | $69K |
| Azithromycin Generic | 96 | 97 | 90 | $339 |
| Theophylline Er Theophylline Anhydrous | 92 | 214 | 31 | $4,448 |
| Spiriva Respimat Tiotropium Bromide | 81 | 105 | 29 | $57K |
| Xolair Omalizumab | 52 | 54 | Under 11 | $233K |
| Levofloxacin Generic | 51 | 51 | 41 | $168 |
| Wixela Inhub Fluticasone Propion/Salmeterol | 42 | 95 | 23 | $8,320 |
Brand drugs: 2,000 claims; generic drugs: 2,422 claims.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Hisham Bismar $614 ($614 in general payments such as food, travel and fees) from 8 companies. The largest payer was Insmed, Inc. with $171.
| Company | Payments | Amount |
|---|---|---|
| Insmed, Inc. INSM | 13 | $171 |
| Jazz Pharmaceuticals Inc. JAZZ | 1 | $150 |
| GlaxoSmithKline, LLC. GSK | 16 | $148 |
| AstraZeneca Pharmaceuticals LP AZN | 3 | $62.71 |
| Mallinckrodt Hospital Products Inc. | 1 | $23.57 |
| Novartis Pharmaceuticals Corporation NVS | 1 | $22.82 |
| Genzyme Corporation SNY | 1 | $20.41 |
| Takeda Pharmaceuticals U.S.A., Inc. TAK | 1 | $15.48 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.